Výsledky vyhledávání - Leip, Eric
- Zobrazuji výsledky 1 - 13 z 13
-
1
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic... Autor Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István
Vydáno 2014Text -
2
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-P... Autor Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István
Vydáno 2014Text -
3
Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib Autor Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo
Vydáno 2016Text -
4
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure Autor Khoury, H. Jean, Cortes, Jorge E., Kantarjian, Hagop M., Gambacorti-Passerini, Carlo, Baccarani, Michele, Kim, Dong-Wook, Zaritskey, Andrey, Countouriotis, Athena, Besson, Nadine, Leip, Eric, Kelly, Virginia, Brümmendorf, Tim H.
Vydáno 2012Text -
5
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors Autor Kantarjian, Hagop M., Cortes, Jorge E., Kim, Dong-Wook, Khoury, H. Jean, Brümmendorf, Tim H., Porkka, Kimmo, Martinelli, Giovanni, Durrant, Simon, Leip, Eric, Kelly, Virginia, Turnbull, Kathleen, Besson, Nadine, Gambacorti-Passerini, Carlo
Vydáno 2014Text -
6
Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors Autor Gambacorti‐Passerini, Carlo, Kantarjian, Hagop M., Kim, Dong‐Wook, Khoury, Hanna J., Turkina, Anna G., Brümmendorf, Tim H., Matczak, Ewa, Bardy‐Bouxin, Nathalie, Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Cortes, Jorge E.
Vydáno 2015Text -
7
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study Autor Gambacorti-Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Kantarjian, Hagop M., Kim, Dong-Wook, Schafhausen, Philippe, Crescenzo, Rocco, Bardy-Bouxin, Nathalie, Shapiro, Mark, Noonan, Kay, Leip, Eric, DeAnnuntis, Liza, Brümmendorf, Tim H., Khoury, H. Jean
Vydáno 2018Text -
8
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Autor Cortes, Jorge E., Kantarjian, Hagop M., Brümmendorf, Tim H., Kim, Dong-Wook, Turkina, Anna G., Shen, Zhi-Xiang, Pasquini, Ricardo, Khoury, H. Jean, Arkin, Steven, Volkert, Angela, Besson, Nadine, Abbas, Richat, Wang, Junyuan, Leip, Eric, Gambacorti-Passerini, Carlo
Vydáno 2011Text -
9
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib Autor Cortes, Jorge E., Khoury, H. Jean, Kantarjian, Hagop, Brümmendorf, Tim H., Mauro, Michael J., Matczak, Ewa, Pavlov, Dmitri, Aguiar, Jean M., Fly, Kolette D., Dimitrov, Svetoslav, Leip, Eric, Shapiro, Mark, Lipton, Jeff H., Durand, Jean-Bernard, Gambacorti-Passerini, Carlo
Vydáno 2016Text -
10
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial Autor Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H.
Vydáno 2018Text -
11
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study Autor Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Abboud, Camille, Gjertsen, Bjørn Tore, Brümmendorf, Tim H., Smith, B. Douglas, Ernst, Thomas, Giraldo-Castellano, Pilar, Olsson-Strömberg, Ulla, Saussele, Susanne, Bardy-Bouxin, Nathalie, Viqueira, Andrea, Leip, Eric, Russell-Smith, T. Alexander, Leone, Jocelyn, Rosti, Gianantonio, Watts, Justin, Giles, Francis J.
Vydáno 2020Text -
12
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial Autor Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W.
Vydáno 2022Text -
13
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up Autor Gambacorti-Passerini, Carlo, Brümmendorf, Tim H, Kim, Dong-Wook, Turkina, Anna G, Masszi, Tamas, Assouline, Sarit, Durrant, Simon, Kantarjian, Hagop M, Khoury, H Jean, Zaritskey, Andrey, Shen, Zhi-Xiang, Jin, Jie, Vellenga, Edo, Pasquini, Ricardo, Mathews, Vikram, Cervantes, Francisco, Besson, Nadine, Turnbull, Kathleen, Leip, Eric, Kelly, Virginia, Cortes, Jorge E
Vydáno 2014Text